Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2020 16:03 ET | Source: Nkarta, Inc.

Nkarta Reports Third Quarter 2020 Financial Results

First patient dosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromesIND application for NKX019...
November 12, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
November 09, 2020 08:02 ET | Source: Nkarta, Inc.

Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
November 05, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Announces November & December 2020 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
October 05, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Announces Leadership Changes

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business OfficerAlicia J. Hager, J.D., Ph.D. to Join as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE...
September 29, 2020 08:02 ET | Source: Nkarta, Inc.

Nkarta Announces October 2020 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
September 08, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Announces September 2020 Virtual Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
August 20, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Second Quarter 2020 Financial Results

Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021Completed construction of cGMP clinical manufacturing facilityCompleted...
July 14, 2020 16:15 ET | Source: Nkarta, Inc.

Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
July 10, 2020 00:44 ET | Source: Nkarta, Inc.

Nkarta Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right